BeyondSpring Inc. (NASDAQ:BYSI) Sees Large Increase in Short Interest

BeyondSpring Inc. (NASDAQ:BYSI) was the target of a significant increase in short interest in December. As of December 15th, there was short interest totaling 2,602,412 shares, an increase of 26.5% from the November 30th total of 2,057,163 shares. Approximately 9.1% of the company’s shares are sold short. Based on an average trading volume of 1,085,584 shares, the short-interest ratio is presently 2.4 days. Based on an average trading volume of 1,085,584 shares, the short-interest ratio is presently 2.4 days. Approximately 9.1% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of BeyondSpring in a research note on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, BeyondSpring presently has an average rating of “Sell”.

BeyondSpring Stock Performance

BYSI stock opened at $1.71 on Wednesday. The company has a market cap of $68.97 million, a price-to-earnings ratio of -11.40 and a beta of 0.53. The business’s 50-day moving average is $1.97 and its two-hundred day moving average is $2.01. BeyondSpring has a fifty-two week low of $0.98 and a fifty-two week high of $3.44.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BeyondSpring stock. Geode Capital Management LLC boosted its holdings in shares of BeyondSpring Inc. (NASDAQ:BYSI) by 951.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 256,212 shares of the company’s stock after purchasing an additional 231,844 shares during the quarter. Geode Capital Management LLC owned about 0.64% of BeyondSpring worth $603,000 as of its most recent SEC filing. 40.29% of the stock is currently owned by institutional investors and hedge funds.

BeyondSpring Company Profile

BeyondSpring Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapies for oncology. Headquartered in Suzhou, China, with corporate operations in New York, the company leverages a versatile drug discovery platform to advance targeted treatments designed to improve outcomes for patients with cancer. BeyondSpring’s pipeline emphasizes agents that modulate the tumor microenvironment and enhance immune response, with an aim to address key unmet needs in supportive care and tumor control.

The company’s lead candidate, plinabulin, is a small-molecule vascular disrupting agent that also exhibits immunomodulatory activity.